IP Library Granted Patent US 7,563,906
Granted Patent B2
US 7,563,906 · App. 10/575,645 · Granted Jul 21, 2009

Indazole derivatives

Assignees: Ube Industries, Ltd.; Santen Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,906
App. No.
10/575,645
Granted
Jul 21, 2009
Kind
B2
Abstract

An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R 1 and R 2 are H or alkyl; R 3 and R 4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R 5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.

Claims (112)

1. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof:

wherein the ring X is a benzene ring or a pyridine ring;

R 1 and R 2 are the same or different and are a hydrogen atom or an alkyl group; or

R 1 and R 2 are bonded together to form an unsubstituted cycloalkane ring;

R 3 is a hydrogen atom, a substituted alkyl group, an unsubstituted alkenyl group, a carboxyl group or an ester or an amide thereof, an amino group or a cyano group, wherein the substituted alkyl group is an alkyl group substituted with one or more groups selected from the group consisting of a hydroxyl group and a hydroxyimino group;

R 4 is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkoxy group, an unsubstituted alkenyloxy group, an unsubstituted cycloalkyloxy group, a substituted or unsubstituted alkyl group, an unsubstituted alkenyl group, an unsubstituted cycloalkyl group, an amino group, a substituted or unsubstituted alkylamino group, a nitro group, a cyano group or a monocyclic heterocycle group, wherein the substituted alkoxy group is an alkoxy group substituted with one or more groups selected from the group consisting of a halogen atom and a cycloalkyl group, the substituted alkyl group is an alkyl group substituted with one or more hydroxyl groups and the substituted alkylamino group is an alkylamino group substituted with one or more aryl groups; and

R 5 is a halogen atom or a hydrogen atom.

2. The compound according to claim 1 , wherein the ring X is a benzene ring or a pyridine ring;

R 1 and R 2 are the same or different and are a hydrogen atom, a methyl group or an ethyl group; or R 1 and R 2 are bonded together to form a cyclopentane ring;

R 3 is a hydrogen atom, a hydroxymethyl group, a hydroxyiminomethyl group, a 1-methylvinyl group, a carboxyl group, a methoxycarbonyl group, an aminocarbonyl group, an amino group or a cyano group;

R 4 is a hydrogen atom, a hydroxyl group, a methoxy group, an ethoxy group, a n-propyloxy group, a n-butyloxy group, an isopropyloxy group, a difluoromethoxy group, a 2-fluoroethoxy group, a 2,2,2-trifluoroethoxy group, an allyloxy group, a cyclopropyloxy group, a cyclopropylmethyloxy group, an ethyl group, a vinyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a cyclopropyl group, an amino group, a methylamino group, a dimethylamino group, a diethylamino group, a benzylamino group, a nitro group, a cyano group, a pyrrolidine ring, a pyrrole ring, a pyrazole ring, an oxazole ring, an isoxazole ring, a piperidine ring, a pyridine ring or a morpholine ring; and

R 5 is a chlorine atom or a hydrogen atom,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein the ring X is a benzene ring or a pyridine ring;

R 1 and R 2 are the same or different and are a hydrogen atom, a methyl group or an ethyl group; or R 1 and R 2 are bonded together to form a cyclopentane ring;

R 3 is a hydrogen atom;

R 4 is a hydroxyl group, a methoxy group, an ethoxy group, a n-propyloxy group, a n-butyloxy group, an isopropyloxy group, a difluoromethoxy group, a 2-fluoroethoxy group, a 2,2,2-trifluoroethoxy group, an allyloxy group, a cyclopropyloxy group, a cyclopropylmethyloxy group, an ethyl group, a vinyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a cyclopropyl group, an amino group, a methylamino group, a dimethylamino group, a diethylamino group, a benzylamino group, a nitro group, a cyano group, a pyrrolidine ring, a pyrrole ring, a pyrazole ring, an oxazole ring, an isoxazole ring, a piperidine ring, a pyridine ring or a morpholine ring; and

R 5 is a chlorine atom or a hydrogen atom,

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , wherein the ring X is connected at the 5-position of the indazole ring, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , wherein when the ring X is a benzene ring, the ring X is connected to the 5-position of the indazole ring and the

group is connected to the 4-position of the benzene ring; or when the ring X is a pyridine ring, the ring X is connected to the 5-position of the indazole ring and

the

group is connected to the 5-position of the pyridine ring,

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 2 , wherein the ring X is connected at the 5-position of the indazole ring, or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 2 , wherein when the ring X is a benzene ring, the ring X is connected to the 5-position of the indazole ring and the

group is connected to the 4-position of the benzene ring; or when the ring X is a pyridine ring, the ring X is connected to the 5-position of the indazole ring and

the

group is connected to the 5-position of the pyridine ring,

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 3 , wherein the ring X is connected at the 5-position of the indazole ring, or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 3 , wherein when the ring X is a benzene ring, the ring X is connected to the 5-position of the indazole ring and the

group is connected to the 4-position of the benzene ring; or when the ring X is a pyridine ring, the ring X is connected to the 5-position of the indazole ring and

the

group is connected to the 5-position of the pyridine ring,

or a pharmaceutically acceptable salt thereof.

10. A compound selected from the group consisting of

5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

1-acetyl-5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-nitro-1H-indazole,

4-amino-5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-benzylamino-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-methylamino-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-methoxycarbonyl-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-carboxy-1H-indazole,

3-aminocarbonyl-5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

3-amino-5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-hydroxyiminomethyl-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-cyano-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-hydroxymethyl-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-3-(1-methylvinyl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-dimethylamino-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-nitro-1H-indazole,

4-(N-acetylamino)-5-[4-(1-amino-1-methylethyl)-phenyl]-1H-indazole,

5-[4-(aminomethyl)phenyl]-4-nitro-1H-indazole,

4-amino-5-[4-(aminomethyl)phenyl]-1H-indazole,

4-amino-5-[4-(1-aminocyclopentyl)phenyl]-1H-indazole,

4-amino-5-[4-(1-amino-1-ethylpropyl)phenyl]-1H-indazole,

5-[4-(aminomethyl)phenyl]-4-dimethylamino-1H-indazole,

5-[4-(1-aminocyclopentyl)phenyl]-4-dimethylamino-1H-indazole,

5-[4-(1-amino-1-ethylpropyl)phenyl]-4-dimethyl-amino-1H-indazole,

5-[4-(1-aminoethyl)phenyl]-4-dimethylamino-1H-indazole,

5-[5-(1-amino-1-methylethyl)-3-chloropyridin-2-yl]-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-ethyl-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-cyclopropyl-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-vinyl-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-diethylamino-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(2-hydroxyethyl)-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-(2-hydroxyethyl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(1-hydroxyethyl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-hydroxymethyl-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-cyano-1H-indazole,

6-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

1-acetyl-6-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyrrol-1-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-isopropoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(piperidin-1-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyrrolidin-1-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(morpholin-4-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-methoxy-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-methoxy-1H-indazole,

5-[5-(1-aminocyclopentyl)pyridin-2-yl]-4-methoxy-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-ethoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-hydroxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-ethoxy-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-isopropoxy-1H-indazole,

5-[5-(1-amino-1-ethylpropyl)pyridin-2-yl]-4-methoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-n-propoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-difluoromethoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(2,2,2-trifluoroethoxy)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-n-butoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(2-fluoroethoxy)-1H-indazole,

4-allyloxy-5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-n-propoxy-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-difluorornethoxy-1H-indazole,

5-[5-(1-amino-1-ethylpropyl)pyridin-2-yl]-4-ethoxy-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyridin-4-yl)-1H-1-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyridin-3-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyridin-2-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyrazol-4-yl)-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-(pyrazol-4-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(oxazol-5-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(pyrazol-3-yl)-1H-indazole,

5-[4-(1-amino-1-methylethyl)phenyl]-4-(isoxazol-5-yl)-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-hydroxyl-1H-indazole,

5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-cyclopropyloxy-1H-indazole,

5-[5-(1-amino-1-ethylpropyl)pyridin-2-yl]-4-cyclopropyloxy-1H-indazole,

5-[4-(1-amino-1-ethylpropyl)phenyl]-4-difluoromethoxy-1H-indazole and 5-[5-(1-amino-1-methylethyl)pyridin-2-yl]-4-cyclopropylmethyloxy-1H-indazole,

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any of claims 1 to 10 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2013
From: SANTEN PHARMACEUTICAL CO., LTD.
To: UBE INDUSTRIES, LTD.
Reel/Frame 029574/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2006
From: HAGIHARA, MASAHIKO; KOMORI, KEN-ICHI; SUNAMOTO, HIDETOSHI; NISHIDA, HIROSHI; MATSUGI, TAKESHI; NAKAJIMA, TADASHI; HATANO, MASAKAZU; KIDO, KAZUTAKA; HARA, HIDEAKI
To: UBE INDUSTRIES, LTD.; SANTEN PHARMACEUTICAL CO., LTD.
Reel/Frame 017864/0206 →
Priority Claims (2)
JP 2003-354917 · Oct 15, 2003 · national
JP 2004-270561 · Aug 20, 2004 · national
Continuity (1)
Related Publication 20070129404A1 · Jun 7, 2007